Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.

Hetherington S, Texter M, Wenzel E, Patti JM, Reynolds L, Shamp T, Swan S.

Antimicrob Agents Chemother. 2006 Oct;50(10):3499-500.

PMID:
17005843
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.

Reilley S, Wenzel E, Reynolds L, Bennett B, Patti JM, Hetherington S.

Antimicrob Agents Chemother. 2005 Mar;49(3):959-62.

PMID:
15728889
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.

Lorusso V, Taroni P, Alvino S, Spinazzi A.

Invest Radiol. 2001 Jun;36(6):309-16.

PMID:
11410750
[PubMed - indexed for MEDLINE]
4.

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.

Weems JJ Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R, Moore T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG Jr.

Antimicrob Agents Chemother. 2006 Aug;50(8):2751-5.

PMID:
16870768
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients.

Spyker DA, Richmond JD, Scheld WM, Bolton WK.

Am J Nephrol. 1985;5(5):355-60.

PMID:
4061504
[PubMed - indexed for MEDLINE]
6.

Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure.

Waaler A, Svaland M, Fauchald P, Jakobsen JA, Kolmannskog F, Berg KJ.

Nephron. 1990;56(1):81-5.

PMID:
2234253
[PubMed - indexed for MEDLINE]
7.

Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.

Dager WE, King JH.

Ann Pharmacother. 2006 Jan;40(1):9-14. Epub 2005 Dec 6.

PMID:
16332944
[PubMed - indexed for MEDLINE]
8.

Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis.

Jillella AP, Dainer PM, Kallab AM, Ustun C.

Am J Hematol. 2002 Nov;71(3):219-22.

PMID:
12410580
[PubMed - indexed for MEDLINE]
9.

Garenoxacin pharmacokinetics in subjects with renal impairment.

Krishna G, Gajjar D, Swan S, Marbury T, Grasela DM, Wang Z.

Curr Med Res Opin. 2007 Mar;23(3):649-57.

PMID:
17355746
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.

Cohen D, Appel GB, Scully B, Neu HC.

Antimicrob Agents Chemother. 1983 Oct;24(4):529-32.

PMID:
6316845
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.

Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R.

J Clin Pharmacol. 2005 Mar;45(3):313-28.

PMID:
15703366
[PubMed - indexed for MEDLINE]
12.

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.

White B, Leon F, White W, Robbie G.

Clin Ther. 2009 Apr;31(4):728-40. doi: 10.1016/j.clinthera.2009.04.019.

PMID:
19446146
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.

Jaffe G, Meyers BR, Hirschman SZ.

Antimicrob Agents Chemother. 1974 Jun;5(6):611-6.

PMID:
15825414
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.

Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL.

J Clin Pharmacol. 2007 Dec;47(12):1466-75. Epub 2007 Oct 22.

PMID:
17954615
[PubMed - indexed for MEDLINE]
15.

Amantadine hydrochloride pharmacokinetics in hemodialysis patients.

Soung LS, Ing TS, Daugirdas JT, Wu MJ, Gandhi VC, Ivanovich PT, Hano JE, Viol GW.

Ann Intern Med. 1980 Jul;93(1):46-9.

PMID:
7396313
[PubMed - indexed for MEDLINE]
16.

Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates.

Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, Kokai-Kun JF, Mond JJ, Kramer WG, Fischer GW.

Antimicrob Agents Chemother. 2009 Jul;53(7):2879-86. doi: 10.1128/AAC.01565-08. Epub 2009 Apr 20.

PMID:
19380597
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.

Puttonen J, Kantele S, Kivikko M, Häkkinen S, Harjola VP, Koskinen P, Pentikäinen PJ.

Clin Pharmacokinet. 2007;46(3):235-46.

PMID:
17328582
[PubMed - indexed for MEDLINE]
18.

Pharmacokinetics of gentamicin in hemodialysis patients: a comparative study between diabetic and non-diabetic patients.

Al-Homrany MA, Irshaid YM, El Sherif AK, Omar HA.

Int Urol Nephrol. 2009;41(3):663-9. doi: 10.1007/s11255-008-9456-2. Epub 2008 Sep 3.

PMID:
18766456
[PubMed - indexed for MEDLINE]
19.

The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized crossover trial.

Wang W, Tonelli M, Hemmelgarn B, Gao S, Johnson JA, Taub K, Manns B; Alberta Kidney Disease Network.

Am J Kidney Dis. 2008 May;51(5):796-803. doi: 10.1053/j.ajkd.2007.12.031. Epub 2008 Apr 2.

PMID:
18436090
[PubMed - indexed for MEDLINE]
20.

Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection.

John JF Jr.

Curr Opin Mol Ther. 2006 Oct;8(5):455-60. Review.

PMID:
17078388
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk